What are cardiotoxic exposures?

Cardiotoxic Exposures

Cardiotoxic exposures encompass chemotherapeutic agents (particularly anthracyclines, trastuzumab, and tyrosine kinase inhibitors), radiation therapy to the chest, environmental toxins (heavy metals, pesticides, pollutants), recreational drugs (cocaine, alcohol), and certain cardiovascular and non-cardiovascular medications that directly damage the heart or vascular system. 1, 2

Chemotherapeutic Agents

Anthracyclines (Highest Risk)

• Doxorubicin and daunorubicin remain the major causes of chemotherapy-induced cardiomyopathy
• Risk increases with cumulative dose: 5% at 400 mg/m², 16% at 500 mg/m², and 26% at 550 mg/m² 1
• Critical caveat: No truly safe dose exists—subclinical cardiac dysfunction occurs in 30% of patients even at doses of 180-240 mg/m², and histopathologic changes appear at doses as low as 240 mg/m² 1
• Mechanism: Poisons topoisomerase 2, causes DNA double-strand breaks, and directly damages cardiomyocytes 1

Targeted Therapies

• Trastuzumab: Causes cardiomyopathy in 1-5% of cancer survivors 1
• Tyrosine kinase inhibitors (e.g., ibrutinib): Broadly suppress cardiac ion currents through kinase-dependent mechanisms 3, 4
• Proteasome inhibitors: Associated with cardiomyopathy 1

Other Chemotherapeutics

• Platinum-based agents: Delay sodium current decay 3
• Immune checkpoint inhibitors: Cause myocarditis and pericarditis 4

Radiation Therapy

Mediastinal and left-sided chest radiation profoundly impacts cardiovascular structures 2:

• Damages vascular structures, valves, pericardium/myocardium, and conduction system
• Affects autonomic nervous system
• Long-term effects require lifelong monitoring

Environmental Toxins

Heavy Metals 3, 5

• Lead (Pb²⁺): Attenuates L-type calcium current (ICaL)
• Nickel (Ni²⁺): Blocks T-type calcium current (ICaT)
• Cadmium (Cd²⁺): Suppresses sodium and calcium currents
• Mercury (Hg²⁺): Inhibits transient outward potassium current (Ito) and ICaL
• Selenium/Zinc: Modulate potassium and calcium currents when deficient or excessive

Pesticides 3

• Pyrethroids (e.g., deltamethrin): Amplify late sodium current, prolong action potential, trigger afterdepolarizations
• Organochlorines (e.g., aldrin): Suppress peak sodium current
• Organophosphates and carbamates: Inhibit calcium, sodium, and potassium currents via oxidative stress
• Fungicides (e.g., tebuconazole): Similar ion channel inhibition
• Glyphosate-based herbicides: Impair L-type calcium current
• Rodenticides (e.g., phosphides): Block hERG potassium channel, mimicking Brugada syndrome

Air Pollutants 3

• Diesel exhaust: Provokes arrhythmias via inflammation and fibrosis
• Carbon monoxide (CO): Inhibits sodium, hERG, and inward rectifier potassium currents through NO/redox mechanisms
• Sulfur dioxide (SO₂): Enhances sodium, transient outward, and calcium currents
• Particulate matter: Activates ROS-CaMKII pathways

Recreational Drugs 6, 7

Cocaine

• Stimulates sympathetic nervous system affecting heart and smooth muscle cells
• Leads to acute cardiotoxicity and progressive heart failure
• Detected in 11.6% of cardiotoxic exposures in toxicology laboratories 7

Alcohol

• Long-term heavy use causes oxidative stress, apoptosis, and decreased contractile protein function 6
• Most frequently detected cardiotoxic agent (57.4% of positive toxicology results) 7

Medications

Cardiovascular Drugs 2, 4

• Beta-blockers and calcium channel blockers: Direct cardiotoxicity, particularly in overdose
• Amlodipine: Most common cardiotoxicant in fatal exposures treated with high-dose insulin (47% of deaths) 8
• Verapamil: Most lethal calcium channel blocker (odds ratio 1.7 for death compared to amlodipine or diltiazem) 8

Non-Cardiovascular Drugs 4

• Antipsychotics: Various cardiac adverse effects
• Venlafaxine: Cardiotoxic potential
• Macrolide antibiotics: Arrhythmias and conduction abnormalities
• Anticholinergic drugs: 15.7% of cardiotoxic exposures 7

Rheumatoid Arthritis Biologics 6

• May interfere with ischemic preconditioning
• Can cause or worsen heart failure

Risk Factors for Cardiotoxicity 1

Individual susceptibility varies based on:

• Cumulative dose of cardiotoxic agent
• Intravenous bolus administration and higher single doses
• Prior chest irradiation
• Concomitant cardiotoxic agents
• Female gender
• Underlying cardiovascular disease
• Age extremes (very young and elderly)
• Genetic variants regulating drug metabolism
• Elevated cardiac biomarkers (troponins) during treatment

Common Pitfalls

The most critical error is assuming low doses of anthracyclines are safe—histopathologic changes occur at cumulative doses as low as 240 mg/m², and reduced cardiac function has been documented at doses of 100 mg/m² 1. Screening for cardiovascular risk factors before initiating any potentially cardiotoxic therapy is mandatory 2, and close collaboration between oncologists and cardiologists improves cardioprotection, therapy adherence, and survival 2.